Viatris Inc. (VTRS)
Price:
11.65 USD
( + 0.06 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Phibro Animal Health Corporation
VALUE SCORE:
5
2nd position
Neurocrine Biosciences, Inc.
VALUE SCORE:
9
The best
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
NEWS
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
prnewswire.com
2025-12-06 09:00:00Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake in Biocon Biologics Limited ("Biocon Biologics"). Under the definitive agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon.
Mark Cuban Takes Aim at FDA Fees
gurufocus.com
2025-12-04 14:08:00Viatris (VTRS) and Teva Pharma (TEVA) could soon face fresh competition after billionaire entrepreneur Mark Cuban called on Washington to scrap a fee he says is
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 11:13:25Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-02 11:03:29Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
globenewswire.com
2025-12-01 09:00:00Management to Participate in 8th Annual Evercore Annual Healthcare Conference Management to Participate in 8th Annual Evercore Annual Healthcare Conference
Viatris to Participate in Upcoming Investor Conferences
prnewswire.com
2025-11-24 08:00:00PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025. The Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:30 a.m.
Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)
prnewswire.com
2025-11-19 19:28:00/PRNewswire/ - S príchodom Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR) uvádza Svetová zdravotnícka organizácia vo svojej Globálnej správe o
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
prnewswire.com
2025-11-19 19:14:00/PRNewswire/ -- Zu Beginn der Weltwoche zur Sensibilisierung für Antibiotikaresistenzen (AMR) zeigt der globale Bericht der Weltgesundheitsorganisation zur
Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe
prnewswire.com
2025-11-19 19:06:00/PRNewswire/ -- Wraz z rozpoczęciem Światowego Tygodnia Wiedzy o Antybiotykach (World AMR Awareness Week) raport Światowej Organizacji Zdrowia z 2025 r. na
Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-18 08:38:47Viatris Inc. ( VTRS ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Hi. Good morning.
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
prnewswire.com
2025-11-13 08:00:00PITTSBURGH , Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide.
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-11 12:01:35Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-06 14:46:14Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
zacks.com
2025-11-06 11:25:18Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com
2025-11-06 10:32:01The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
zacks.com
2025-11-06 09:15:28Viatris (VTRS) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.75 per share a year ago.
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
prnewswire.com
2025-12-06 09:00:00Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake in Biocon Biologics Limited ("Biocon Biologics"). Under the definitive agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon.
Mark Cuban Takes Aim at FDA Fees
gurufocus.com
2025-12-04 14:08:00Viatris (VTRS) and Teva Pharma (TEVA) could soon face fresh competition after billionaire entrepreneur Mark Cuban called on Washington to scrap a fee he says is
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 11:13:25Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-02 11:03:29Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
globenewswire.com
2025-12-01 09:00:00Management to Participate in 8th Annual Evercore Annual Healthcare Conference Management to Participate in 8th Annual Evercore Annual Healthcare Conference
Viatris to Participate in Upcoming Investor Conferences
prnewswire.com
2025-11-24 08:00:00PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025. The Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:30 a.m.
Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)
prnewswire.com
2025-11-19 19:28:00/PRNewswire/ - S príchodom Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR) uvádza Svetová zdravotnícka organizácia vo svojej Globálnej správe o
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
prnewswire.com
2025-11-19 19:14:00/PRNewswire/ -- Zu Beginn der Weltwoche zur Sensibilisierung für Antibiotikaresistenzen (AMR) zeigt der globale Bericht der Weltgesundheitsorganisation zur
Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe
prnewswire.com
2025-11-19 19:06:00/PRNewswire/ -- Wraz z rozpoczęciem Światowego Tygodnia Wiedzy o Antybiotykach (World AMR Awareness Week) raport Światowej Organizacji Zdrowia z 2025 r. na
Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-18 08:38:47Viatris Inc. ( VTRS ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Hi. Good morning.
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
prnewswire.com
2025-11-13 08:00:00PITTSBURGH , Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide.
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
seekingalpha.com
2025-11-11 12:01:35Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-06 14:46:14Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
zacks.com
2025-11-06 11:25:18Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com
2025-11-06 10:32:01The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
zacks.com
2025-11-06 09:15:28Viatris (VTRS) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.75 per share a year ago.